

Conclusion

Substantial HDV infection among HIV/HBV co-infected study participants was observed in the current study. In view of the need for additional medication required for the treatment of HDV infection, we therefore recommend HDV infection screening for HIV/HBV infected individuals. Inability to carry out HDV RNA which is the most important marker in the diagnosis and follow up of HDV infection was a limitation of the current study. Another limitation of this study was inability to screen for other disease conditions that may raise AST levels.

References

- [1].Coffie PA, Tchounga BK, Bado G, Kabran M, Minta DK, Wandeler G et al. Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West Africa. *BMC Infectious Diseases* 2017, **17**:466. <https://doi.org/10.1186/s12879-017-2568-5>.
- [2].Greenwood D, Slack R and Peutherer J. *Medical Microbiology: A guide to Microbial Infections: Pathogenesis, Immunity, Laboratory Diagnosis and control 15th Edition*, Churchill Livingstone, Edinburg, England, 1997, pp 443, 446-447.
- [3].Hønge BL, Jespersen S, Medina C, Té DdS, da Silva ZJ, Lewin S et al. Hepatitis B and Delta Virus Are Prevalent but Often Subclinical Co-Infections among HIV Infected Patients in Guinea-Bissau, West Africa: A Cross-Sectional Study. *PLoS ONE* 2014, **9**(6): e99971. <https://doi.org/10.1371/journal.pone.0099971>.
- [4].Ifeorah I, Bakarey AS, Adeniji A and Onyemelukwe N. Seroprevalence of Hepatitis B and Delta viruses among HIV infected population attending Antiretroviral clinic in selected health facilities in Abuja Nigeria. *Journal of Immunoassay and Immunochemistry* 2017, **10**.1080/15321819.2017.
- [5].Joint United Nation Programme on HIV/AIDS. Global AIDS Update. 2016 [Cited 2016, March 13]. Available at: http://www.unaids.org/site/default/media_asset/global-AIDSupdate-2016_en.pdf.
- [6].Joint United Nation Programme on HIV/AIDS. Nigeria Global Acquired Immunodeficiency Syndrome Response Country Progress Report. 2015 [Cited 2017, March12]. Available at: http://www.unaids.org/sites/default/files/countryNGA_narrative_report_2015.pdf.
- [7].Katwesigye E, Seremba E, Semitala F and Ocamo P. Low Sero-prevalence of hepatitis delta antibodies in HIV/ hepatitis B co-infected patients attending an urban HIV clinic in Uganda. *Afri Health Sci* 2016, **16**(4): 1089-1093. <http://dx.doi.org/10.4314/ahs.v16i4.26>.
- [8].Mendes-Correa MC, Gomes-Gouvêa MS, Alvarado-Mora MV, Da Silva MH, Lázari C, Cavalcanti NCS, et al. Hepatitis delta in HIV/HBV co-infected patients in Brazil: is it important? *International Journal of Infectious Diseases* 2011, **15**(12): pp e828-e832.
- [9].Motamedifar M, Taheri M, Lankarani KB, Gholami M, Lari MA, Faramarzi H, et al. The Prevalence and Risk Factors of Hepatitis Delta Virus in HIV/HBV Co-Infected Patients in Shiraz, Iran, 2012. *Iran J Med Sci* 2015, **40**(5): 448-453.
- [10]. Mumtaz K, Hamid SS, Adil S, Afaq A, Islam M, Abid S et al. Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan. *J Gastroenterol Hepatol.* 2005, **20**(10):1503-7.
- [11].Musa BM, Bussell S, Borodo MM, Samaila AA and Femi OL. Prevalence of hepatitis B virus in Nigeria, 2000-2013; A systemic review and meta-analysis. *Nigeria Journal of Clinical Practice* 2015, **18**(2): 163-172.
- [12]. O'Shea RS. Liver disease related to hepatitis B remains an important public health concern and major cause of morbidity and mortality. It also presents a common challenging problem for practicing physicians. 2010. [Cited 2012, December 10]. Available at: www.clevelandclinimed.com/medicalpubs/hepatology/hepatitis-B.
- [13].Roy PK. Hepatitis D: Background, Etiology, Epidemiology. [Cited 2018, January 10]. Available at: <http://www.emedicine.medscape.com/article/178038-overview>.
- [14]. Sultanik P and Pol S. Hepatitis Delta Virus: E pidemiology, Natural Course and Treatment. *J Infect Dis Ther* 2016, **4**:271. doi: 10.4172/2332-0877.1000271.
- [15]. Thio CL. Hepatitis B and Human immunodeficiency virus infection. *Hepatology* 2009, **49**(5): 138-145.